Publication: 3166

Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)
      QxMD      Google Scholar   
Citation:
Ther Adv Med Oncol vol 12
Year:
2020
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Book Volume:
9
Parents:
549   574   589   642  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
Bayer; Genentech  
Grants:
U10CA180821, U10CA180882, UG1CA232760, UG1CA189808, U24CA196171  
Corr. Author:
 
Authors:
                     
Networks:
HAWAII, KS055, LAPS-MN026, MCRC, METROMIN, SANFORD   
Study
NCCTG-N054C
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
antiangiogenesis, bevacizumab, colorectal cancer, single nucleotide polymorphism, sorafenib